MBCOF (MBCOF)
0.14
0.00 (0.00%)
Latest Headlines
Marvel Biosciences receives Australian patent allowance for MB-204
June 8, 2026 7:00 AM - StreetInsider
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
June 8, 2026 7:00 AM - Globe NewsWire
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026 7:30 AM - Globe NewsWire
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026 7:00 AM - Globe NewsWire
Marvel Biosciences secures funding for autism drug trial from 5 Horizons
April 7, 2026 12:26 PM - StreetInsider
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026 12:26 PM - Globe NewsWire
Marvel Biosciences secures funding for autism drug trial
April 7, 2026 7:37 AM - StreetInsider
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026 7:30 AM - Globe NewsWire
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
March 25, 2026 7:30 AM - Globe NewsWire
Marvel Biosciences receives US patent for autism drug candidate MB-204
March 18, 2026 7:02 AM - StreetInsider
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
March 18, 2026 7:02 AM - StreetInsider
Full Article List
